The effects of systemic immunomodulatory treatments on COVID ‐19 outcomes in patients with atopic dermatitis: Results from the global SECURE‐AD registry

Covid-19: WHO recommends baricitinib and sotrovimab to treat patients

(2022) Zosia Kmietowicz   BMJ-British Medical Journal

Associations between COVID-19 and skin conditions identified through epidemiology and genomic studies

(2021) Matthew T. Patrick et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Management of patients with atopic dermatitis undergoing systemic therapy during COVID‐19 pandemic in Italy: Data from the DA‐COVID‐19 registry

(2021) Andrea Chiricozzi et al.   ALLERGY

Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry

(2021) Anja Strangfeld et al.   ANNALS OF THE RHEUMATIC DISEASES

Learning from Disease Registries During a Pandemic: Moving Towards an International Federation of Patient Registries.

(2021) Dmitri Wall et al.   CLINICS IN DERMATOLOGY

Dermatology COVID-19 Registries

(2021) Esther E. Freeman et al.   DERMATOLOGIC CLINICS

The risk of COVID-19 infection in patients with atopic dermatitis: A retrospective cohort study

(2021) Jashin J. Wu et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

COVID-19 Symptoms Are Attenuated in Moderate-to-Severe Atopic Dermatitis Patients Treated with Dupilumab

(2021) Benjamin Ungar et al.   Journal of Allergy and Clinical Immunology-In Practice

Association Between Tumor Necrosis Factor Inhibitors and the Risk of Hospitalization or Death Among Patients With Immune-Mediated Inflammatory Disease and COVID-19

(2021) Zara Izadi et al.   JAMA Network Open

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

(2020) Chaolin Huang et al.   LANCET

Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry

(2020) Milena Gianfrancesco et al.   ANNALS OF THE RHEUMATIC DISEASES

Dupilumab and COVID ‐19: What should we expect?

(2020) Cataldo Patruno et al.   Dermatologic Therapy

Corticosteroids, but not TNF Antagonists, are Associated with Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results from an International Registry

(2020) Erica J. Brenner et al.   GASTROENTEROLOGY

No evidence of increased risk for COVID‐19 infection in patients treated with Dupilumab for atopic dermatitis in a high‐epidemic area ‐ Bergamo, Lombardy, Italy

(2020) A. Carugno et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Baricitinib for COVID-19: a suitable treatment?

(2020) Ennio G Favalli et al.   LANCET INFECTIOUS DISEASES

Dupilumab Provides Favorable Safety and Sustained Efficacy for up to 3 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis

(2020) Lisa A. Beck et al.   AMERICAN JOURNAL OF CLINICAL DERMATOLOGY

Use of Baricitinib in Patients with Moderate and Severe COVID-19

(2020) Boghuma K Titanji et al.   CLINICAL INFECTIOUS DISEASES

Management of adult patients with severe atopic dermatitis treated with dupilumab during COVID ‐19 pandemic: A single‐center real‐life experience

(2020) Mariateresa Rossi et al.   Dermatologic Therapy

Epidemiology of COVID‐19: A Systematic Review and Meta‐analysis of Clinical Characteristics, Risk factors and Outcomes

(2020) Jie Li et al.   JOURNAL OF MEDICAL VIROLOGY

Risk of systemic infections in adults with atopic dermatitis: a nationwide cohort study

(2020) Catherine Droitcourt et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

International collaboration and rapid harmonization across dermatologic COVID-19 registries

(2020) Esther E. Freeman et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Atopic dermatitis

(2020) Sinéad M Langan et al.   LANCET

Factors associated with COVID-19-related death using OpenSAFELY

(2020) Elizabeth J. Williamson et al.   NATURE

Dexamethasone in Hospitalized Patients with Covid-19 — Preliminary Report

(2020)   NEW ENGLAND JOURNAL OF MEDICINE

The COVID-19 Cytokine Storm; What We Know So Far

(2020) Dina Ragab et al.   Frontiers in Immunology

Phenotype and kinetics of SARS-CoV-2-specific T cells in COVID-19 patients with acute respiratory distress syndrome

(2020) Daniela Weiskopf et al.   Science Immunology

Admission hyperglycemiaas a predictor of mortality in patients hospitalized with COVID-19 regardless of diabetes status: Data from the Spanish SEMI-COVID-19 Registry

(2020) Francisco Javier Carrasco-Sánchez et al.   ANNALS OF MEDICINE

Factors associated with adverse COVID-19 outcomes in patients with psoriasis – insights from a global registry-based study

(2020) Satveer K. Mahil et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Cytokine release syndrome in COVID-19: Innate immune, vascular, and platelet pathogenic factors differ in severity of disease and sex

(2020) Aaron C. Petrey et al.   JOURNAL OF LEUKOCYTE BIOLOGY

Comparative Risk of Serious Infections With Biologic and/or Immunosuppressive Therapy in Patients with Inflammatory Bowel Diseases: a Systematic Review and Meta-analysis

(2019) Siddharth Singh et al.   Clinical Gastroenterology and Hepatology

Risk of Serious Infection in Patients Receiving Systemic Medications for the Treatment of Psoriasis

(2019) Erica D. Dommasch et al.   JAMA Dermatology

Infliximab is associated with an increased risk of serious infection in patients with psoriasis in the United Kingdom and Republic of Ireland: results from the British Association of Dermatologists Biologic Interventions Register (BADBIR)

(2018) Z.Z.N. Yiu et al.   BRITISH JOURNAL OF DERMATOLOGY

New insights into the epidemiology of childhood atopic dermatitis

(2013) C. Flohr et al.   ALLERGY

World Medical Association Declaration of Helsinki

(2013)   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Efficacy and safety of systemic treatments for moderate-to-severe atopic dermatitis: A systematic review

(2013) Evelien Roekevisch et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY